[go: up one dir, main page]

NO20035632L - Selv-emulgerende formuleringer av kolesterylester-overforingsproteininhibitorer - Google Patents

Selv-emulgerende formuleringer av kolesterylester-overforingsproteininhibitorer

Info

Publication number
NO20035632L
NO20035632L NO20035632A NO20035632A NO20035632L NO 20035632 L NO20035632 L NO 20035632L NO 20035632 A NO20035632 A NO 20035632A NO 20035632 A NO20035632 A NO 20035632A NO 20035632 L NO20035632 L NO 20035632L
Authority
NO
Norway
Prior art keywords
self
transfer protein
cholesteryl ester
protein inhibitors
ester transfer
Prior art date
Application number
NO20035632A
Other languages
English (en)
Other versions
NO20035632D0 (no
Inventor
Michael Jon Gumkowski
Sharad Balasaheb Murdande
Michael Ellis Perlman
Franco LOMBARDO
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20035632D0 publication Critical patent/NO20035632D0/no
Publication of NO20035632L publication Critical patent/NO20035632L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Colloid Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO20035632A 2001-06-21 2003-12-17 Selv-emulgerende formuleringer av kolesterylester-overforingsproteininhibitorer NO20035632L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30002801P 2001-06-21 2001-06-21
PCT/IB2002/001571 WO2003000295A2 (en) 2001-06-21 2002-05-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors

Publications (2)

Publication Number Publication Date
NO20035632D0 NO20035632D0 (no) 2003-12-17
NO20035632L true NO20035632L (no) 2004-02-18

Family

ID=23157363

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20035632A NO20035632L (no) 2001-06-21 2003-12-17 Selv-emulgerende formuleringer av kolesterylester-overforingsproteininhibitorer

Country Status (33)

Country Link
US (2) US6962931B2 (no)
EP (1) EP1453544A2 (no)
JP (1) JP2005500314A (no)
KR (1) KR20040015746A (no)
CN (1) CN1635911A (no)
AP (1) AP2002002559A0 (no)
AR (1) AR034599A1 (no)
BG (1) BG108486A (no)
BR (1) BR0210505A (no)
CA (1) CA2455288A1 (no)
CR (1) CR7163A (no)
CZ (1) CZ20033341A3 (no)
EA (1) EA200301139A1 (no)
EC (1) ECSP034875A (no)
EE (1) EE200400024A (no)
GT (1) GT200200124A (no)
HN (1) HN2002000153A (no)
HU (1) HUP0400263A2 (no)
IL (1) IL158765A0 (no)
IS (1) IS7014A (no)
MA (1) MA27034A1 (no)
MX (1) MXPA04000014A (no)
NO (1) NO20035632L (no)
OA (1) OA12619A (no)
PA (1) PA8548601A1 (no)
PE (1) PE20030128A1 (no)
PL (1) PL368850A1 (no)
SK (1) SK15172003A3 (no)
SV (1) SV2003001103A (no)
TN (1) TNSN03139A1 (no)
UY (1) UY27344A1 (no)
WO (1) WO2003000295A2 (no)
ZA (1) ZA200308561B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534370A (ja) * 1998-12-30 2002-10-15 デクセル リミテッド サイクロスポリンを送達するための分散可能な濃縮物
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
JP4031232B2 (ja) * 2001-11-09 2008-01-09 カプスゲル・ジャパン株式会社 新規カプセル
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
EP1485442A4 (en) * 2002-03-01 2009-11-11 Cesi Chemical A Flotek Co COMPOSITION AND METHOD FOR CLEANING A WELL
US20040175341A1 (en) * 2003-03-04 2004-09-09 Manning Monna Marie Microemulsion for cosmetic or pharmaceutical use containing an active ingredient
ATE534381T1 (de) * 2003-03-17 2011-12-15 Japan Tobacco Inc Pharmazeutische cetp-inhibitor-zusammensetzungen
JP2006520810A (ja) * 2003-03-17 2006-09-14 日本たばこ産業株式会社 Ｓ−［２−（［［１−（２−エチルブチル）シクロヘキシル］カルボニル］アミノ）フェニル］２−メチルプロパンチオエートの経口吸収性を増加させる方法
CN1761463A (zh) * 2003-03-17 2006-04-19 日本烟草产业株式会社 提高s－[2－([[1－(2－乙基丁基)环己基]羰基]氨基)苯基]－2－甲基丙硫代酸酯口服生物利用度的方法
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2532931A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
BRPI0414671A (pt) * 2003-09-30 2006-11-21 Pfizer Prod Inc inibidores da cetp e metabolitos dos mesmos
ES2332051T3 (es) * 2003-10-08 2010-01-25 Eli Lilly And Company Compuestos y procedimientos para tratar dislipidemia.
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US9040558B2 (en) 2004-12-31 2015-05-26 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
US7623458B2 (en) * 2005-09-30 2009-11-24 The Boeing Company System and method for providing integrated services across cryptographic boundaries in a network
ATE516016T1 (de) * 2005-12-05 2011-07-15 Merck Sharp & Dohme Selbstemulgierende formulierungen von cetp- hemmern
EP1982705B8 (en) * 2005-12-31 2012-08-22 Tasly Pharmaceutical Group Co., Ltd. Pharmaceutical composition containing chenopodium ambrosioides extract and its preparation process and application
WO2008005352A2 (en) * 2006-06-30 2008-01-10 Schering Corporation Solid dose formulations of a thrombin receptor antagonist
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
US9222013B1 (en) 2008-11-13 2015-12-29 Cesi Chemical, Inc. Water-in-oil microemulsions for oilfield applications
AU2009326326B2 (en) * 2008-12-08 2015-05-21 F. Hoffmann-La Roche Ag Combined drug administration
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
SMT202000093T1 (it) 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
BR112013029778A2 (pt) * 2011-05-20 2017-01-17 Aventis Pharma Inc composição farmacêutica que compreende fexofenadina
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
IN2014CN02290A (no) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
WO2013059729A1 (en) * 2011-10-21 2013-04-25 First Tech International Limited Tocotrienol compositions
DK2838970T3 (en) 2012-04-15 2017-03-20 Flotek Chemistry Llc Density formulations for foam filling
US11407930B2 (en) 2012-05-08 2022-08-09 Flotek Chemistry, Llc Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US9200192B2 (en) 2012-05-08 2015-12-01 Cesi Chemical, Inc. Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
WO2014128564A2 (en) * 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US11254856B2 (en) 2013-03-14 2022-02-22 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9321955B2 (en) 2013-06-14 2016-04-26 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US9068108B2 (en) 2013-03-14 2015-06-30 Cesi Chemical, Inc. Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10590332B2 (en) 2013-03-14 2020-03-17 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US10941106B2 (en) 2013-03-14 2021-03-09 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US10421707B2 (en) 2013-03-14 2019-09-24 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US11180690B2 (en) 2013-03-14 2021-11-23 Flotek Chemistry, Llc Diluted microemulsions with low surface tensions
US10717919B2 (en) 2013-03-14 2020-07-21 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9428683B2 (en) 2013-03-14 2016-08-30 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US9868893B2 (en) 2013-03-14 2018-01-16 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9464223B2 (en) 2013-03-14 2016-10-11 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10053619B2 (en) 2013-03-14 2018-08-21 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US10000693B2 (en) 2013-03-14 2018-06-19 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9884988B2 (en) 2013-03-14 2018-02-06 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10577531B2 (en) 2013-03-14 2020-03-03 Flotek Chemistry, Llc Polymers and emulsions for use in oil and/or gas wells
US10287483B2 (en) 2013-03-14 2019-05-14 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol
CN104706587A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种依托咪酯脂肪乳浓缩液、其制备方法及用途
CN104706689A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种鸦胆子油脂肪乳浓缩液、其制备方法及用途
CN104706586A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种丁酸氯维地平脂肪乳浓缩液、其制备方法及用途
US9890625B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with an obstruction material
US9890624B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with a polymeric material
CA2891278C (en) 2014-05-14 2018-11-06 Cesi Chemical, Inc. Methods and compositions for use in oil and / or gas wells
CA3042567C (en) 2014-07-28 2021-12-14 Flotek Chemistry, Llc Methods and compositions related to gelled layers in oil and/or gas wells
WO2016071756A1 (en) * 2014-11-04 2016-05-12 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
CN104546710A (zh) * 2014-12-20 2015-04-29 长沙佰顺生物科技有限公司 一种安塞曲匹纳米乳及其制备方法
CN104490775A (zh) * 2014-12-20 2015-04-08 长沙佰顺生物科技有限公司 一种安塞曲匹脂肪乳及其制备方法
KR101590072B1 (ko) * 2014-12-23 2016-01-29 한미약품 주식회사 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
WO2016191744A1 (en) 2015-05-28 2016-12-01 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
BR112018071048A2 (pt) 2016-04-15 2019-05-07 Janssen Sciences Ireland Uc combinações e métodos que compreendem um inibidor da montagem de capsídeos
US10934472B2 (en) 2017-08-18 2021-03-02 Flotek Chemistry, Llc Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
WO2019108971A1 (en) 2017-12-01 2019-06-06 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
EP3886813B1 (en) * 2018-11-26 2023-03-22 Hepion Pharmaceuticals, Inc. Pharmaceutical formulations of cyclosporine analogs
EA202192793A1 (ru) 2019-04-11 2022-01-12 Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью
CN110252395B (zh) * 2019-07-01 2020-10-16 湖北远大生命科学与技术有限责任公司 一种用于制备高纯度牛磺酸的催化剂及其应用
US11104843B2 (en) 2019-10-10 2021-08-31 Flotek Chemistry, Llc Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency
FR3110852B1 (fr) * 2020-05-27 2024-03-15 Centre Nat Rech Scient Emulsions pour liberation controlee de medicaments
US11512243B2 (en) 2020-10-23 2022-11-29 Flotek Chemistry, Llc Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods
EP4267132A1 (en) 2020-12-28 2023-11-01 Dr. Reddy's Laboratories Ltd. Celecoxib for treating pain

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
WO1995031979A1 (en) 1994-05-19 1995-11-30 R.P. Scherer International Corporation Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
WO1996033697A1 (fr) * 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
BR9713811A (pt) 1996-06-19 2004-03-02 Novartis Ag Preparações de cápsula macia contendo ciclosporina
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
AU9297798A (en) * 1997-09-16 1999-04-05 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
US6063762A (en) 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
WO1999041237A1 (en) * 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
AU6161099A (en) * 1998-09-25 2000-04-17 Monsanto Company Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
JP2002534370A (ja) 1998-12-30 2002-10-15 デクセル リミテッド サイクロスポリンを送達するための分散可能な濃縮物
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US6482862B1 (en) * 1999-12-20 2002-11-19 G.D. Searle & Co. Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
WO2003000294A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
WO2003000235A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
BR0307516A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida
ES2305434T3 (es) * 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR20050088190A (ko) * 2002-12-20 2005-09-02 화이자 프로덕츠 인코포레이티드 콜레스테릴 에스터 전달 단백질 억제제 및 ｈｍｇ-ｃｏａ환원 효소 억제제를 포함하는 투약 형태

Also Published As

Publication number Publication date
EE200400024A (et) 2004-06-15
PE20030128A1 (es) 2003-02-28
GT200200124A (es) 2003-09-22
CZ20033341A3 (cs) 2004-10-13
IS7014A (is) 2003-10-31
SK15172003A3 (en) 2004-11-03
CA2455288A1 (en) 2003-01-03
PA8548601A1 (es) 2003-09-05
AR034599A1 (es) 2004-03-03
HUP0400263A2 (hu) 2005-03-29
ECSP034875A (es) 2004-01-28
MXPA04000014A (es) 2004-05-21
KR20040015746A (ko) 2004-02-19
US6962931B2 (en) 2005-11-08
ZA200308561B (en) 2004-11-17
HN2002000153A (es) 2002-11-05
SV2003001103A (es) 2003-03-18
CN1635911A (zh) 2005-07-06
TNSN03139A1 (fr) 2005-12-23
EA200301139A1 (ru) 2004-12-30
BR0210505A (pt) 2004-05-18
AP2002002559A0 (en) 2002-06-30
UY27344A1 (es) 2003-01-31
NO20035632D0 (no) 2003-12-17
EP1453544A2 (en) 2004-09-08
US20030022944A1 (en) 2003-01-30
WO2003000295A2 (en) 2003-01-03
IL158765A0 (en) 2004-05-12
CR7163A (es) 2004-02-23
OA12619A (en) 2006-06-12
US20060014788A1 (en) 2006-01-19
WO2003000295A3 (en) 2004-05-27
PL368850A1 (en) 2005-04-04
BG108486A (bg) 2005-03-31
MA27034A1 (fr) 2004-12-20
JP2005500314A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
NO20035632D0 (no) Selv-emulgerende formuleringer av kolesterylester- overföringsproteininhibitorer
EE200300052A (et) Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid
NO20041582L (no) Antistoffinhibitorer av GDF-8 og anvendelse derav
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
NO20043506L (no) Kontrollert frigivende farmasoytiske doseringsformer av en kolesterylester overforingsproteininhibitor
NO20031623L (no) Liposomal formulering av mitoxantron
DK1392319T3 (da) Sammensætninger af hypotensiv lipid (prostaglandin) og timolol og fremgangsmåder til anvendelse deraf
EP1501532A4 (en) PEPTIDE INHIBITORS OF PROTEIN KINASE C
IS6508A (is) Lyfjasamsetningar af glycogen fosfórýlasa lötum
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
NO993717D0 (no) Anvendelse av gastrointestinale lipase-inhibitorer
NO20020287L (no) Prodroge av en ICE-inhibitor
NO20020185L (no) Formuleringer av IL-11
DK1216025T3 (da) Dispersionsformuleringer indeholdende lipaseinhibitorer
NO20044916L (no) Preparater av sulfinylacetamid
NO20050563L (no) N-aryl-piperidinsubstituerte bifenylkarboksamider som inhibitorer av apolipoprotein B-sekresjon
DK1333810T3 (da) Orale selvemulgerende doseringsformuleringer af pyranon-protease-inhibitorer
NO20041968L (no) Anvendelse av cystationin
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
EE200200429A (et) Kolesteroolestri ja vahaestri sünteesi duaalsed inhibiitorid rasunäärme häirete jaoks
EP1534158A4 (en) COMPOSITIONS AND METHODS FOR CRYOSURGERY
EP1674100A4 (en) ANGIOGENESIS INHIBITORS
NO20035668D0 (no) Antitumorformuleringer av tioxantenon
NO20044424L (no) Fremgangsmate for fremstilling av sertindol
SE0202026D0 (sv) Isolation of nucleic acids

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application